+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Impetigo Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767762
  • Report
  • 49 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • HEC Group
  • LEO Foundation
  • Lytix Biopharma AS
  • MORE
The global clinical trial report- “2019 Impetigo Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Impetigo. It presents in-depth analysis of Impetigo clinical trials across markets and companies. The research work is for providing complete understanding into trends in Impetigo.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Impetigo clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Impetigo

The research work is prepared through extensive and continuous research on Impetigo trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Impetigo patients are identified
  • The report includes panorama of Impetigo clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Impetigo clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • HEC Group
  • LEO Foundation
  • Lytix Biopharma AS
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Impetigo Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Impetigo Clinical Trials by Region
2.2.2 Average Enrollment of Impetigo Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Impetigo Treatment, 2019

3. Region wise Impetigo Clinical Trials
3.1 Asia Pacific Impetigo Clinical Trials by Country
3.2 Europe Impetigo Clinical Trials by Country
3.3 North America Impetigo Clinical Trials by Country
3.4 Middle East and Africa Impetigo Clinical Trials by Country
3.5 South and Central America Impetigo Clinical Trials by Country

4. Impetigo Clinical Trial Trends
4.1 Start Year wise Impetigo Clinical Trials
4.2 Phase wise Impetigo Clinical Trials
4.3 Trial Status wise Impetigo Clinical Trials
4.4 Trial Type wise Impetigo Clinical Trials

5. Impetigo Average Enrollment Trends
5.1 Average Enrollment in Impetigo Trials by Year
5.2 Average Enrollment in Impetigo Trials by Phase
5.3 Average Enrollment in Impetigo Trials by Status
5.4 Average Enrollment in Impetigo Trials by Type of Trial

6. Companies Participating in Impetigo Clinical Trials
6.1 Impetigo Trials by Sponsor Type
6.2 Impetigo Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Impetigo Trials- Phase 1
7.2 Impetigo Trials- Phase 2
7.3 Impetigo Trials- Phase 3
7.4 Impetigo Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Impetigo Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Impetigo Clinical Trials and Enrolment
Figure 5: Europe - Country wise Impetigo Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Impetigo Clinical Trials and Enrolment
Figure 7: North America - Country wise Impetigo Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Impetigo Clinical Trials and Enrolment
Figure 9: Impetigo Clinical Trials by Phase
Figure 10: Impetigo Clinical Trials by Trial Status
Figure 11: Impetigo Clinical Trials by Type
Figure 12: Impetigo Clinical Trials by Sponsor Type
Figure 13: Impetigo Clinical Trials by Leading Sponsors
Figure 14: Impetigo Average Enrollment by Phase
Figure 15: Impetigo Average Enrollment by Trial Status
Figure 16: Impetigo Average Enrollment by Type
Figure 17: Impetigo- Average Enrolment by Type of Sponsors
Figure 18: Impetigo- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Impetigo Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Impetigo Clinical Trials and Enrolment
Table 5: Europe - Country wise Impetigo Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Impetigo Clinical Trials and Enrolment
Table 7: North America - Country wise Impetigo Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Impetigo Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Impetigo Average Enrollment by Phase
Table 15: Impetigo Average Enrollment by Trial Status
Table 16: Impetigo Average Enrollment by Type
Table 17: Impetigo- Average Enrolment by Type of Sponsors
Table 18: Impetigo- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Foamix Pharmaceuticals Ltd
  • GlaxoSmithKline Plc
  • Grupo Ferrer Internacional SA
  • HEC Group
  • Jubilant Life Sciences Ltd
  • Lambda Therapeutic Research Ltd
  • LEO Foundation
  • Lytix Biopharma AS
  • NovaBay Pharmaceuticals Inc
  • Novum Pharmaceutical Research Services Inc
Note: Product cover images may vary from those shown
Adroll
adroll